BACKGROUND: @entity135 is a comparatively rare and aggressive @entity5 . Our goal was to examine the experience of @entity135 @entity1 seen over a 15-year period at the University of Washington Medical Center and compare this with the published experience of other centers in terms of demographics, histology, treatment, and survival rate. METHODS: We reviewed surgical pathology slides and clinical treatment records of 13 @entity1 who were treated at the University of Washington Medical Center between 1981 and 1996. A total of 17 cases from 13 @entity1 (13 @entity5 and 4 recurrences) were studied. RESULTS: There was a slight male predominance, with a male:female ratio of 1.6:1, and median age at diagnosis of 40.9 years (range 22 to 75 years), both slightly higher than has been generally reported. Three of 13 @entity1 had recognized risk factors for the development of @entity421 : 2 with a history of prior radiotherapy and 1 with @entity4261 . All surgical pathology specimens were examined independently by two pathologists for histologic grading and typing. At initial presentation, 9/13 (69%) cases had conventional (osteoblastic) histology; 2/13 (15%) were fibroblastic, 1 chondroblastic (8%) and 1 parosteal (8%). Eight of 13 (62%) cases were high grade at initial presentation. Four of 13 (30%) of the @entity5 were low grade 2, of which did not recur over a median follow-up period of 24 months. The other 2 low-grade @entity5 later recurred locally, as high-grade @entity421 , after disease-free intervals of 1 year and 14 years, respectively. One @entity1 had an intermediate-grade @entity5 which has not recurred as of last follow-up. Combined-modality treatment, including surgery with or without radiotherapy and/or chemotherapy, was given depending on the histologic grade, surgical margins, and recurrence. Some @entity1 with low-grade @entity5 had surgery only. There were 5 local recurrences, 1 of these following a disease-free interval of 14 years. One @entity1 had 3 separate recurrences at the same site. Ten of 13 (77%) are alive and disease-free. Of the 3 deaths, 1 was related to radiation-induced @entity39 , without evidence of recurrent @entity5 . The project 5-year overall survival in this series is 72%, with a mean follow-up of 58 months (median, 36 months). Of those receiving neoadjuvant chemotherapy, 6/7 have survived to the present. CONCLUSION: Given the limitations of a small @entity1 population, our data suggest that neoadjuvant chemotherapy may provide benefit in terms of survival. Longer follow-up will be necessary to support this conclusion. Our data also show that our population has a higher-than-average age of onset, low presence of risk factors, and better survival rate in comparison with the published series from other institutions.

XXXX at the University of Washington.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck osteosarcoma', 'Head and neck osteosarcoma'] @entity39 :: ('MESH:D009336', 'Disease') :: ['brain necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'malignancy', 'tumors'] @entity4261 :: ('MESH:D010001', 'Disease') :: ["Paget's disease"] @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcomas', 'osteosarcoma']
@entity135 :: (MESH:D006258,Disease) :: ['Head and neck osteosarcoma']
